IP Library › Granted Patent US 7,923,004

Granted Patent B2

US 7,923,004 · App. 11/974,744 · Granted Apr 12, 2011

4-ethynyl pyrazole derivative compounds and methods for treatment of HCV

Assignee: XTL Biopharmaceuticals Ltd.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,923,004
App. No.: 11/974,744
Granted: Apr 12, 2011
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount.

Claims (277)

1. A compound of the formula I:

or a pharmaceutically acceptable salt thereof, wherein:

ring A is selected from a 5- or 6-membered aromatic rings which may optionally contain 0 to 3 ring heteroatoms;

each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) a —O—R 11 , —(CH 2 ) a —N(R 12 )(R 13 ), —(CH 2 ) a —N(R 11 )—(CH 2 ) b C(O)R 14 , —(CH 2 ) a —N(R 11 )SO 2 R 11 , —(CH 2 ) a —SR 11 , —(CH 2 ) a —C(O)R 14 —(CH 2 ) a —C(O)—(CH 2 ) b OR 11 , —(CH 2 ) a —C(O)—(CH 2 ) b N(R 12 )(R 13 ), —(CH 2 ) a O—(CH 2 ) b —C(O)R 14 , —(CH 2 ) a —OC(O)—(CH 2 ) b N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , —SOR 11 , —SO 3 R 11 , —SO 2 N(R 12 )(R 13 ), cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and a heterocyclic group;

additionally or alternatively two R 1 substituents on adjacent ring atoms may be combined to form a fused 5 or 6-membered ring, wherein the fused 5- or 6-membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with one or more substituents selected from R 11 ;

each R 11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

each R 12 and R 13 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and a heterocyclic group; or R 12 and R 13 may be taken together with the nitrogen to which they are attached form a 5- to 7-membered ring which may optionally contain a further heteroatom and may be optionally substituted with up to three substituents selected from halo, CN, NO 2 , alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, and a heterocyclic group;

each R 14 is independently selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, -alkyl-O-alkyl, -alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

a is 0 to 6;

b is 0 to 6;

R 3 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) z —O—R 31 , —(CH 2 ) z —N(R 32 )(R 33 ), —(CH 2 ) w —C(O)R 34 , —(CH 2 ) w C(O)—N(R 32 )(R 33 ), —(CH 2 ) w —SO 2 —R 31 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 31 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

R 32 and R 33 are independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group; or R 32 and R 33 may be taken together with the nitrogen to which they are attached form a 5- to 7-membered ring which may optionally contain a further heteroatom;

R 34 is selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

w is 0 to 6;

z is 1 to 6;

R 4 is independently selected from H, CN, CF 3 , alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

ring B is selected from a 5- or 6-membered aromatic rings which may optionally contain 0 to 3 ring heteroatoms;

R 5 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

X 1 is selected from CH 2 , O, S, SO 2 , and —N(R 101 )—;

R 101 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —C(═O)—R 102 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 102 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —N(R 103 )(R 104 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 103 and R 104 are independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group, or R 103 and R 104 may be taken together with the nitrogen to which they are attached form a 5- to 7-membered ring which may optionally contain a further heteroatom;

X 2 is selected from —CH 2 —, —CH 2 CH 2 —, —C(═O)CH 2 —, and —C(═O)—;

Z is selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, —(CH 2 ) c —O—R 15 , —(CH 2 ) c —N(R 16 )(R 17 ), —(CH 2 ) c —N(R 15 )—(CH 2 ) e C(O)R 18 , —(CH 2 ) c —SR 15 , —(CH 2 ) d —C(O)R 18 , —(CH 2 ) d —C(O)—(CH 2 ) c OR 15 , —(CH 2 ) d —C(O)—(CH 2 ) e N(R 16 )(R 17 ), —(CH 2 ) c O—(CH 2 ) e —C(O)R 18 , —(CH 2 ) c OC(O)—(CH 2 ) e N(R 16 )(R 17 ), —SO 2 R 15 , —SO 3 R 15 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 15 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

each R 16 and R 17 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and a heterocyclic group; or R 16 and R 17 may be taken together with the nitrogen to which they are attached form a 5- to 7-membered ring which may optionally contain a further heteroatom and may be optionally substituted with up to three substituents selected from halo, CN, NO 2 , alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, and a heterocyclic group;

each R 18 is independently selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

c is 1 to 6;

d is 0 to 6;

e is 0 to 6;

or Z is a group having the formula -A-B—C—R 8 , wherein

A is selected from —C(═O)—, and —SO 2 —;

B is selected from —(CH 2 ) x —CH(R 6 )—(CH 2 ) y —, and

x is 0 to 4;

y is 0 to 4;

R 6 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) f —Y—(CH 2 ) g —R 61 , —(CH 2 ) f —N(R 62 )(R 63 ), —(CH 2 ) f —N(R 61 )—(CH 2 ) g C(O)R 64 ,—(CH 2 ) f —N(R 61 )SO 2 R 61 , —(CH 2 ) f —SR 61 , —(CH 2 ) f —C(O)R 64 , —(CH 2 ) f —C(O)—(CH 2 ) g OR 61 , —(CH 2 ) f —C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(O)R 64 , —(CH 2 ) f —Y—C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(═NOR 61 )—R 61 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 61 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

each R 62 and R 63 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and a heterocyclic group; or R 62 and R 63 may be taken together with the nitrogen to which they are attached form a 5- to 7-membered ring which may optionally contain a further heteroatom and may be optionally substituted with up to three substituents selected from halo, CN, NO 2 , alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, and a heterocyclic group;

each R 64 is independently selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, -alkyl-O-alkyl, -alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

Y is selected from a chemical bond, —O—, and aryl;

f is 1 to 6;

g is 0 to 6;

C is selected from —N(R 7 )—C(═O)—, —N(R 7 )—S(═O) 2 —, and —CH 2 —;

R 7 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 8 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) r —O—(CH 2 )—R 81 , —(CH 2 ) r —N(R 82 )(R 83 ), —(CH 2 ) r —N(R 81 )—(CH 2 ) s C(O)R 84 , —(CH 2 ) r —N(R 81 )SO 2 R 81 , —(CH 2 ) r —SR 81 , —(CH 2 ) r —C(O)R 84 , —(CH 2 ) r —C(O)—(CH 2 ) s OR 81 , —(CH 2 ) r —R 81 , —(CH 2 ) r —C(O)(CH 2 ) s N(R 82 )(R 83 ), —(CH 2 ) r O—(CH 2 ) s —C(O)R 84 , —(CH 2 ) r OC(O)—(CH 2 ) s N(R 82 )(R 83 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 81 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

each R 82 and R 83 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aralkyl, aryl and a heterocyclic group; or R 82 and R 83 may be taken together with the nitrogen to which they are attached form a 5- to 7-membered ring which may optionally contain a further heteroatom and may be optionally substituted with up to three substituents selected from halo, CN, NO 2 , oxo, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, and a heterocyclic group;

each R 84 is independently selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, -alkyl-O-alkyl, -alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

r is 0 to 6;

s is 0 to 6; and

n is 0 to 5.

2. The compound of claim 1 , having the formula II

or a pharmaceutically acceptable salt thereof, wherein:

ring A is selected from a 5- or 6-membered aromatic rings which may optionally contain 0 to 3 ring heteroatoms;

each R 1 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) a —O—R 11 , —(CH 2 ) a —N(R 12 )(R 13 ), —(CH 2 ) a —N(R 11 )—(CH 2 ) b C(O)R 14 , —(CH 2 ) a —N(R 11 )SO 2 R 11 , —(CH 2 ) a —SR 11 , (CH 2 ) a —C(O)R 14 , —(CH 2 ) a —C(O)—(CH 2 ) b OR 11 , —(CH 2 ) a —C(O)—(CH 2 ) b N(R 12 )(R 13 ), —(CH 2 ) a O—(CH 2 ) b —C(O)R 14 , —(CH 2 ) a OC(O)—(CH 2 ) b N(R 12 )(R 13 ), CN, CF 3 , NO 2 , SO 2 , —SOR 11 , —SO 3 R 11 , —SO 2 N(R 12 )(R 13 ), cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and a heterocyclic group;

each R 11 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

a is 0 to 6;

b is 0 to 6;

R 31 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

R 34 is selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

w is 0 to 6;

z is 1 to 6;

R 4 is independently selected from H, CN, CF 3 , alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

ring B is selected from a 5- or 6-membered aromatic rings which may optionally contain 0 to 3 ring heteroatoms;

R 5 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

X 1 is selected from CH 2 , O, S, SO 2 , and —N(R 101 )—;

R 101 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —C(═O)—R 102 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 102 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —N(R 103 )(R 104 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

X 2 is selected from —CH 2 —, —CH 2 CH 2 —, —C(═O)CH 2 —, and —C(═O)—;

R 6 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) f —Y—(CH 2 ) g —R 61 , —(CH 2 ) f —N(R 62 )(R 63 ), —(CH 2 ) f —N(R 61 )—(CH 2 ) g C(O)R 64 , —(CH 2 ) f —N(R 61 )SO 2 R 61 , —(CH 2 ) f —SR 61 , —(CH 2 ) f —C(O)R 64 , —(CH 2 ) f —C(O)—(CH 2 ) g OR 61 , —(CH 2 ) f —C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(O)R 64 , —(CH 2 ) f —Y—C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) r —Y—(CH 2 ) g —C(═NOR 61 )—R 61 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 61 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

Y is selected from a chemical bond, —O—, and aryl;

f is 1 to 6;

g is 0 to 6;

R 7 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 8 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) r —O—(CH 2 ) s —R 81 , —(CH 2 ) r —N(R 82 )(R 83 ), —(CH 2 ) r —N(R 81 )—(CH 2 ) s C(O)R 84 , —(CH 2 ) r —N(R 81 )SO 2 R 81 , —(CH 2 ) r —SR 81 , —(CH 2 ) r —C(O)R 84 , —(CH 2 ) r —C(O)—(CH 2 ) s OR 81 , —(CH 2 ) r —R 81 , —(CH 2 ) r —C(O)—(CH 2 ) s N(R 82 )(R 83 ), —(CH 2 ) s —C(O)R 84 , —(CH 2 ) r OC(O)—(CH 2 ) s N(R 82 )(R 83 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 81 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

r is 0 to 6;

s is 0 to 6; and

n is 0 to 5.

3. The compound of claim 1 , having the formula III:

or a pharmaceutically acceptable salt thereof, wherein:

ring A is selected from a 5- or 6-membered aromatic rings which may optionally contain 0 to 3 ring heteroatoms;

each R 9 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 )—O—R 91 , —(CH 2 ) a —N(R 92 )(R 93 ), —(CH 2 ) a —N(R 91 )—(CH 2 ) b C(O)R 94 , —(CH 2 ) a —N(R 91 )SO 2 R 91 , —(CH 2 ) a —SR 91 , —(CH 2 ) a —C(O)R 94 , —(CH 2 ) a —C(O)—(CH 2 ) b OR 91 , —(CH 2 ) a —C(O)—(CH 2 ) b N(R 92 )(R 93 ), —(CH 2 ) a O—(CH 2 ) b —C(O)R 94 , —(CH 2 ) a OC(O)—(CH 2 ) b N(R 92 )(R 93 ), CN, CF 3 , NO 2 , SO 2 , —SOR 91 , —SO 3 R 91 , —SO 2 N(R 92 )(R 93 ), cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and a heterocyclic group;

additionally or alternatively two R 9 substituents on adjacent ring atoms may be combined to form a fused 5 or 6-membered ring, wherein the fused 5- or 6-membered ring may contain from 0 to 3 ring heteroatoms and may be further substituted with one or more substituents selected from R 91 ;

each R 91 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

each R 92 and R 93 are independently selected from H, alkyl, cycloalkyl, cycloalkenyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, aralkyl, aryl and a heterocyclic group; or R 92 and R 93 may be taken together with the nitrogen to which they are attached form a 5- to 7-membered ring which may optionally contain a further heteroatom and may be optionally substituted with up to three substituents selected from halo, CN, NO 2 , alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, and a heterocyclic group;

each R 94 is independently selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, -alkyl-O-alkyl, -alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

a is 0 to 6;

b is 0 to 6;

R 2 is selected from OH, SH, and NH 2 ;

R 31 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

R 34 is selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

w is 0 to 6;

z is 1 to 6;

R 4 is independently selected from H, CN, CF 3 , alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

ring B is selected from a 5- or 6-membered aromatic rings which may optionally contain 0 to 3 ring heteroatoms;

R 5 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

X 1 is selected from CH 2 , O, S, SO 2 , and —N(R 101 )—;

R 101 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —C(═O)—R 102 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 102 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —N(R 103 )(R 104 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

X 2 is selected from —CH 2 —, —CH 2 CH 2 —, —C(═O)CH 2 —, and —C(═O)—;

R 6 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) f —Y—(CH 2 ) g —R 61 , —(CH 2 ) f —N(R 62 )(R 63 ), —(CH 2 ) f —N(R 61 )—(CH 2 ) g C(O)R 64 , —(CH 2 ) f —N(R 61 )SO 2 R 61 , —(CH 2 ) f —SR 61 , —(CH 2 ) f —C(O)R 64 , —(CH 2 ) f —C(O)—(CH 2 ) g OR 61 , —(CH 2 ) f —C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(O)R 64 , —(CH 2 ) f —Y—C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(═NOR 61 )—R 61 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 61 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

Y is selected from a chemical bond, —O—, and aryl;

f is 1 to 6;

g is 0 to 6;

R 7 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 8 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) r —O—(CH 2 ) s —R 81 , —(CH 2 ) r —N(R 82 )(R 83 ), —(CH 2 ) r —N(R 81 )—(CH 2 ) s C(O)R 84 , —(CH 2 ) r —N(R 81 )SO 2 R 81 , —(CH 2 ) r —SR 81 , —(CH 2 ) r —C(O)R 84 , —(CH 2 ) r —C(O)—(CH 2 ) s OR 81 , —(CH 2 ) r —R 81 , —(CH 2 ) r —C(O)—(CH 2 ) s N(R 82 )(R 83 ), —(CH 2 ) r O—(CH 2 ) s —C(O)R 84 , —(CH 2 ) r OC(O)—(CH 2 ) s N(R 82 )(R 83 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 81 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

r is 0 to 6;

s is 0 to 6; and

m is 0 to 4.

4. The compound of claim 1 , having the formula IV:

or a pharmaceutically acceptable salt thereof, wherein:

each R 9 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) a —O—R 91 , —(CH 2 ) a —N(R 92 )(R 93 ), —(CH 2 ) a —N(R 91 )—(CH 2 ) b C(O)R 94 , —(CH 2 ) a —N(R 91 )SO 2 R 91 , —(CH 2 ) a —SR 91 , —(CH 2 ) a —C(O)R 94 , —(CH 2 ) a —C(O)—(CH 2 ) b OR 91 , —(CH 2 ) a —C(O)—(CH 2 ) b N(R 92 )(R 93 ), —(CH 2 ) a O—(CH 2 ) b —C(O)R 94 , —(CH 2 ) a OC(O)—(CH 2 ) b N(R 92 )(R 93 ), CN, CF 3 , NO 2 , SO 2 , —SOR 91 , —SO 3 R 91 , —SO 2 N(R 92 )(R 93 ), cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and a heterocyclic group;

each R 91 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

a is 0 to 6;

b is 0 to 6;

R 2 is selected from OH, SH, and NH 2 ;

R 31 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

R 34 is selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

w is 0 to 6;

z is 1 to 6;

R 4 is independently selected from H, CN, CF 3 , alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 5 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

X 1 is selected from CH 2 , O, S, SO 2 , and —N(R 101 )—;

R 101 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —C(═O)—R 102 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 102 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —N(R 103 )(R 104 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 6 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) f —Y—(CH 2 ) g R 61 , —(CH 2 ) f —N(R 62 )(R 63 ), —(CH 2 ) f N(R 61 )—(CH 2 ) g C(O)R 64 , —(CH 2 ) f —N(R 61 )SO 2 R 61 , —(CH 2 ) f —SR 61 , —(CH 2 ) f —C(O)R 64 , —(CH 2 ) f —C(O)—(CH 2 ) g OR 61 , —(CH 2 ) f —C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(O)R 64 , —(CH 2 ) f Y—C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(═NOR 61 )—R 61 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 61 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

Y is selected from a chemical bond, —O—, and aryl;

f is 1 to 6;

g is 0 to 6;

R 7 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 8 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) r —O—(CH 2 ) s —R 81 , —(CH 2 ) r —N(R 82 )(R 83 ), —(CH 2 ) r —N(R 81 )—(CH 2 ) s C(O)R 84 , —(CH 2 ) r —N(R 81 )SO 2 R 81 , —(CH 2 ) r —SR 81 , —(CH 2 ) r —C(O)R 84 , —(CH 2 ) r —C(O)—(CH 2 ) s OR 81 , —(CH 2 ) r —R 81 , —(CH 2 ) r —C(O)—(CH 2 ) s N(R 82 )(R 83 ), —(CH 2 ) r O—(CH 2 ) s —C(O)R 84 , —(CH 2 ) r OC(O)—(CH 2 ) s N(R 82 )(R 83 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 81 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

r is 0 to 6;

s is 0 to 6; and

m is 0 to 4.

5. The compound of claim 1 , having the formula V:

or a pharmaceutically acceptable salt thereof, wherein:

each R 9 is independently selected from alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) a —O—R 91 , —(CH 2 ) a —N(R 92 )(R 93 ), —(CH 2 ) a —N(R 91 )—(CH 2 ) b C(O)R 94 , —(CH 2 ) a —N(R 91 )SO 2 R 91 , —(CH 2 ) a —SR 91 , —(CH 2 ) a —C(O)R 94 , —(CH 2 ) a —C(O)—(CH 2 ) b OR 91 , —(CH 2 ) a —C(O)—(CH 2 ) b N(R 92 )(R 93 ), —(CH 2 ) a O—(CH 2 ) b —C(O)R 94 , —(CH 2 ) a OC(O)—(CH 2 ) b N(R 92 )(R 93 ), CN, CF 3 , NO 2 , SO 2 , —SOR 91 , —SO 3 R 91 , —SO 2 N(R 92 )(R 3 ), cycloalkyl, cycloalkenyl, halo, phosphate, phosphonate, aryl and a heterocyclic group;

each R 91 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

a is 0 to 6;

b is 0 to 6;

R 3 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) z —O—R 31 , —(CH 2 ) z —N(R 32 )(R 33 ), —(CH 2 ) w —C(O)R 34 , —(CH 2 ) w C(O)—N(R 32 )(R 33 ), —(CH 2 ) w —SO 2 —R 31 cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 31 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

R 34 is selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

w is 0 to 6;

z is 1 to 6;

R 6 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) f —Y—(CH 2 ) g —R 61 , —(CH 2 ) f —N(R 62 )(R 63 ), —(CH 2 ) f —N(R 61 )—(CH 2 ) g C(O)R 64 , —(CH 2 ) f —N(R 61 )SO 2 R 61 , —(CH 2 ) f —SR 61 , —(CH 2 ) f —C(O)R 64 , —(CH 2 ) f —C(O)—(CH 2 ) g OR 61 , —(CH 2 ) f —C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(O)R 64 , —(CH 2 ) g —Y—C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) g —Y—(CH 2 ) g —C(═NOR 61 )—R 61 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 61 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

Y is selected from a chemical bond, —O—, and aryl;

f is 1 to 6;

g is 0 to 6;

X 1 is selected from CH 2 , O, S, SO 2 , and —N(R 101 )—;

R 101 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —C(═O)—R 102 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 102 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —N(R 103 )(R 104 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 8 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) r —O—(CH 2 ) s R 81 , —(CH 2 ) r —N(R 82 )(R 83 ), —(CH 2 ) r —N(R 81 )—(CH 2 ) s C(O)R 84 , —(CH 2 ) r —N(R 81 )SO 2 R 81 , —(CH 2 ) r —SR 81 , —(CH 2 ) r —C(O)R 84 , —(CH 2 ) r —C(O)—(CH 2 ) s OR 81 , —(CH 2 ) r —R 81 , —(CH 2 ) r —C(O)—(CH 2 ) s N(R 82 )(R 83 ), —(CH 2 ) r O(CH 2 ) s —C(O)R 84 , —(CH 2 ) r OC(O)—(CH 2 ) s N(R 82 )(R 83 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 81 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

r is 0 to 6;

s is 0 to 6; and

m is 0 to 4.

6. The compound of claim 1 , having the formula VI:

or a pharmaceutically acceptable salt thereof, wherein:

each R 91 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

a is 0 to 6;

b is 0 to 6;

R 2 is selected from OH, SH, and NH 2 ;

R 31 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

R 34 is selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

w is 0 to 6;

z is 1 to 6;

R 4 is independently selected from H, CN, CF 3 , alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 5 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

X 1 is selected from CH 2 , O, S, SO 2 , and —N(R 101 )—;

R 101 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —C(═O)—R 102 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 102 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —N(R 103 )(R 104 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 6 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) f —Y—(CH 2 ) g —R 61 , —(CH 2 ) f —N(R 62 )(R 63 ), —(CH 2 ) f —N(R 61 )—(CH 2 ) g C(O)R 64 , —(CH 2 ) f —N(R 61 )SO 2 R 61 , —(CH 2 ) f —SR 61 , —(CH 2 ) f —C(O)R 64 , —(CH 2 ) f —C(O)—(CH 2 ) g OR 61 , —(CH 2 ) f —C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(O)R 64 , —(CH 2 ) f —Y—C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(═NOR 61 )—R 61 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 61 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

Y is selected from a chemical bond, —O—, and aryl;

f is 1 to 6;

g is 0 to 6;

R 7 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 8 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) r —O—(CH 2 ) s —R 81 , —(CH 2 ) r —N(R 82 )(R 83 ), —(CH 2 ) r —N(R 81 )—(CH 2 ) s C(O)R 84 , —(CH 2 ) r —N(R 81 )SO 2 R 81 , —(CH 2 ) r —SR 81 , —(CH 2 ) r —C(O)R 84 , —(CH 2 ) r —C(O)—(CH 2 ) s OR 81 , —(CH 2 ) r —R 81 , —(CH 2 ) r —C(O)—(CH 2 ) s N(R 82 )(R 83 ), —(CH 2 ) r O—(CH 2 ) s —C(O)R 84 , —(CH 2 ) r OC(O)—(CH 2 ) s N(R 82 )(R 83 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 81 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

r is 0 to 6;

s is 0 to 6; and

m is 0 to 4.

7. The compound of claim 1 , having the VII:

or a pharmaceutically acceptable salt thereof, wherein:

each R 91 is independently selected from H, alkyl, alkyl-O-alkyl, alkyl-O-aryl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

a is 0 to 6;

b is 0 to 6;

R 31 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

R 34 is selected from H, alkyl, —OH, —O-alkyl, —O-aryl, —O-aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

w is 0 to 6;

z is 1 to 6;

R 6 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) f —Y—(CH 2 ) g —R 61 , —(CH 2 ) f —N(R 62 )(R 63 ), —(CH 2 ) f —N(R 61 )—(CH 2 ) g C(O)R 64 , —(CH 2 ) f —N(R 61 )SO 2 R 61 , —(CH 2 ) f —SR 61 , —(CH 2 ) f C(O)R 64 , —(CH 2 ) f —C(O)—(CH 2 ) g OR 61 , —(CH 2 ) f —C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(O)R 64 , —(CH 2 ) f —Y—C(O)—(CH 2 ) g N(R 62 )(R 63 ), —(CH 2 ) f —Y—(CH 2 ) g —C(═NOR 61 )—R 61 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 61 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

Y is selected from a chemical bond, —O—, and aryl;

f is 1 to 6;

g is 0 to 6;

X 1 is selected from CH 2 , O, S, SO 2 , and —N(R 101 )—;

R 101 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —C(═O)—R 102 , cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 102 is selected from H, alkyl, alkenyl, alkynyl, aralkyl, —N(R 103 )(R 104 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

R 8 is independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, —(CH 2 ) r —O—(CH 2 ) s —R 81 , —(CH 2 ) r —N(R 82 )(R 83 ), —(CH 2 ) r —N(R 81 )—(CH 2 ) s C(O)R 84 , —(CH 2 ) r —N(R 81 )SO 2 R 81 , —(CH 2 ) r —SR 81 , —(CH 2 ) r —C(O)R 84 , —(CH 2 ) r —C(O)—(CH 2 ) s OR 81 , —(CH 2 ) r —R 81 , —(CH 2 ) r C(O)—(CH 2 ) s N(R 82 )(R 83 ), —(CH 2 ) r O—(CH 2 ) s —C(O)R 84 , —(CH 2 ) r OC(O)—(CH 2 ) s N(R 82 )(R 83 ), cycloalkyl, cycloalkenyl, aryl and a heterocyclic group;

each R 81 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aryl and a heterocyclic group;

r is 0 to 6;

s is 0 to 6; and

m is 0 to 4.

8. The compound of claim 1 , having the structure selected from:

9. The compound of claim 1 , having the structure selected from:

10. A method of treating HCV infection in a human comprising administering a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

11. A method of treating HCV infection in a human comprising administering a therapeutically effective amount of a combination of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one additional agent selected from an interferon, ribavirin, an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV IRES inhibitor, an HCV Helicase, an HCV ATPase inhibitor, an NS5A modulator, or an HCV NS2 inhibitor.

12. The method of claim 11 , wherein the at least one additional agent is an interferon.

13. The method of claim 12 , wherein the at least one additional agent is α-interferon.

Assignments (3)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2011

From: LIU, YIXIN

To: XTL BIOPHARMACEUTICALS LTD.

Reel/Frame 025590/0338 →

LICENSE Recorded Apr 7, 2008

From: XTL BIOPHARMACEUTICALS LTD.

To: PRESIDIO PHARMACEUTICALS, INC.

Reel/Frame 020762/0273 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2008

From: LI, GOULIN; FATHI, REZA; YANG, ZHEN; LIAO, YUN; ZHU, QIANG; LAM, ANGELA; SANDRASAGRA, ANTHONY; NAWOSCHIK, KENNETH; CHO, HYUN-JOON; CAO, JIE; RUOQIU, WU; WOBBE, C. RICHARD

To: XTL BIOPHARMACEUTICALS LTD.

Reel/Frame 020672/0520 →

Continuity (4)

Provisional Application 60933565 · Jun 6, 2007

Provisional Application 60925528 · Apr 20, 2007

Provisional Application 60851643 · Oct 13, 2006

Related Publication 20090041723A1 · Feb 12, 2009